Literature DB >> 21443269

Susceptibility of the antioxidant selenoenyzmes thioredoxin reductase and glutathione peroxidase to alkylation-mediated inhibition by anticancer acylfulvenes.

Xiaodan Liu1, Kathryn E Pietsch, Shana J Sturla.   

Abstract

Selenium, in the form of selenocysteine, is a critical component of some major redox-regulating enzymes, including thioredoxin reductase (TrxR) and glutathione peroxidase (Gpx). TrxR has emerged as an anticancer target for drug development due to its elevated expression level in many aggressive human tumors. Acylfulvenes (AFs) are semisynthetic derivatives of the natural product illudin S and display improved cytotoxic selectivity profiles. AF and illudin S alkylate cellular macromolecules. Compared to AFs, illudin S more readily reacts with thiol-containing small molecules such as cysteine, glutathione, and cysteine-containing peptides. However, a previous study indicates that the reactivity of AFs and illudin S with glutathione reductase, a thiol-containing enzyme, is inversely correlated with the reactivity toward small molecule thiols. In this study, we investigate mechanistic aspects underlying the enzymatic and cellular effects of the AFs and illudin S on thioredoxin reductase. Both AF and HMAF were found to inhibit mammalian TrxR in the low- to submicromolar range, but illudin S was significantly less potent. TrxR inhibition by AFs was shown to be irreversible, concentration- and time-dependent, and mediated by alkylation of C-terminus active site Sec/Cys residues. In contrast, neither AFs nor illudin S inhibits Gpx, demonstrating that enzyme structure-specific small molecule interactions have a significant influence over the inherent reactivity of the Sec residue. In human cancer cells, TrxR activity can be inhibited by low micromolar concentrations of all three drugs. Finally, it was demonstrated that preconditioning cells by the addition of selenite to the cell culture media results in an enhancement in cell sensitivity toward AFs. These data suggest potential strategies for increasing drug activity by combination treatments that promote selenium enzyme activity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21443269      PMCID: PMC3210965          DOI: 10.1021/tx2000152

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  74 in total

1.  Reduction of dehydroascorbate to ascorbate by the selenoenzyme thioredoxin reductase.

Authors:  J M May; S Mendiratta; K E Hill; R F Burk
Journal:  J Biol Chem       Date:  1997-09-05       Impact factor: 5.157

2.  Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene.

Authors:  V N Gladyshev; K T Jeang; T C Stadtman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

3.  Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia.

Authors:  M Berggren; A Gallegos; J R Gasdaska; P Y Gasdaska; J Warneke; G Powis
Journal:  Anticancer Res       Date:  1996 Nov-Dec       Impact factor: 2.480

4.  The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from Escherichia coli.

Authors:  L D Arscott; S Gromer; R H Schirmer; K Becker; C H Williams
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

5.  The oxidation of selenocysteine is involved in the inactivation of glutathione peroxidase by nitric oxide donor.

Authors:  M Asahi; J Fujii; T Takao; T Kuzuya; M Hori; Y Shimonishi; N Taniguchi
Journal:  J Biol Chem       Date:  1997-08-01       Impact factor: 5.157

6.  (Hydroxymethyl)acylfulvene: an illudin derivative with superior antitumor properties.

Authors:  T C McMorris; M J Kelner; W Wang; J Yu; L A Estes; R Taetle
Journal:  J Nat Prod       Date:  1996-09       Impact factor: 4.050

7.  Mechanisms of the regulation of thioredoxin reductase activity in cancer cells by the chemopreventive agent selenium.

Authors:  A Gallegos; M Berggren; J R Gasdaska; G Powis
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

8.  Michael-type addition of illudin S, a toxic substance from Lampteromyces japonicus, with cysteine and cysteine-containing peptides in vitro.

Authors:  K Tanaka; T Inoue; Y Tezuka; T Kikuchi
Journal:  Chem Pharm Bull (Tokyo)       Date:  1996-02       Impact factor: 1.645

9.  Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.

Authors:  J R MacDonald; C C Muscoplat; D L Dexter; G L Mangold; S F Chen; M J Kelner; T C McMorris; D D Von Hoff
Journal:  Cancer Res       Date:  1997-01-15       Impact factor: 12.701

10.  Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents.

Authors:  M J Kelner; T C McMorris; L Estes; W Wang; K M Samson; R Taetle
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

View more
  7 in total

1.  Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions.

Authors:  Paul A Jackson; John C Widen; Daniel A Harki; Kay M Brummond
Journal:  J Med Chem       Date:  2016-12-20       Impact factor: 7.446

2.  Improved efficacy of acylfulvene in colon cancer cells when combined with a nuclear excision repair inhibitor.

Authors:  Paul M van Midwoud; Shana J Sturla
Journal:  Chem Res Toxicol       Date:  2013-11-05       Impact factor: 3.739

3.  Cellular Protection of SNAP-25 against Botulinum Neurotoxin/A: Inhibition of Thioredoxin Reductase through a Suicide Substrate Mechanism.

Authors:  Hajime Seki; Song Xue; Sabine Pellett; Peter Šilhár; Eric A Johnson; Kim D Janda
Journal:  J Am Chem Soc       Date:  2016-04-20       Impact factor: 15.419

4.  A Chemical Proteomic Analysis of Illudin-Interacting Proteins.

Authors:  Philipp Le; Matthew B Nodwell; Jürgen Eirich; Stephan A Sieber
Journal:  Chemistry       Date:  2019-09-03       Impact factor: 5.236

5.  A machine learning-based gene signature of response to the novel alkylating agent LP-184 distinguishes its potential tumor indications.

Authors:  Umesh Kathad; Aditya Kulkarni; Joseph Ryan McDermott; Jordan Wegner; Peter Carr; Neha Biyani; Rama Modali; Jean-Philippe Richard; Panna Sharma; Kishor Bhatia
Journal:  BMC Bioinformatics       Date:  2021-03-02       Impact factor: 3.169

Review 6.  Selenium compounds, apoptosis and other types of cell death: an overview for cancer therapy.

Authors:  Carmen Sanmartín; Daniel Plano; Arun K Sharma; Juan Antonio Palop
Journal:  Int J Mol Sci       Date:  2012-08-02       Impact factor: 6.208

7.  Thioredoxin reductase is a major regulator of metabolism in leukemia cells.

Authors:  Sheelarani Karunanithi; Ruifu Liu; Yongchun Hou; Giancarlo Gonzalez; Natasha Oldford; Anne Jessica Roe; Nethrie Idipilly; Kalpana Gupta; Chandra Sekhar Amara; Satwikreddy Putluri; Grace Kyueun Lee; Juan Valentin-Goyco; Lindsay Stetson; Stephen A Moreton; Vasanta Putluri; Shyam M Kavuri; Yogen Saunthararajah; Marcos de Lima; Gregory P Tochtrop; Nagireddy Putluri; David N Wald
Journal:  Oncogene       Date:  2021-07-08       Impact factor: 9.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.